KR860003219A - 아다만탄아민유도체의 제조방법 - Google Patents

아다만탄아민유도체의 제조방법 Download PDF

Info

Publication number
KR860003219A
KR860003219A KR1019850008081A KR850008081A KR860003219A KR 860003219 A KR860003219 A KR 860003219A KR 1019850008081 A KR1019850008081 A KR 1019850008081A KR 850008081 A KR850008081 A KR 850008081A KR 860003219 A KR860003219 A KR 860003219A
Authority
KR
South Korea
Prior art keywords
radical
compound
derivative
preparing
pyroglutamic acid
Prior art date
Application number
KR1019850008081A
Other languages
English (en)
Other versions
KR920003837B1 (ko
Inventor
라루엘 끌로드 (외 2)
Original Assignee
끌로드 라루엘
빵메디까 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 끌로드 라루엘, 빵메디까 소시에떼아노님 filed Critical 끌로드 라루엘
Publication of KR860003219A publication Critical patent/KR860003219A/ko
Application granted granted Critical
Publication of KR920003837B1 publication Critical patent/KR920003837B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

아다만탄아민유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 다음식(Ⅰ)에 해당하는 N-(아다만탄-I-일) 피롤리딘-5-온-2-카르복사미드 유도체
    여기서 R은 수소를 나타내거나 알콕시, 티오알킬 또는 니트릴 그룹에 의해 치환되거나 치환되지 않은 탄소원자가 1-7개인 곧은 또는 가지달린 알킬 라디칼을 나타내거나 또는 다음 식(Ⅱ)의 아실라디칼을 나타낸다.
    이 때 R1은 탄소원자가 1-7개인 곧은 또는 가지달린 알킬라디칼, 하나 또는 그 이상의 메틸렌 그룹에 의해 카르보닐 라디칼에 결합되는 고리도 가능한 탄소원자가 5-7개인 사이클로알킬라디칼, 니트로그룹, C1-C3알콕시 그룹, C1-C3알킬 그룹 또는 할로겐 원자와 같은 치환제에 의해 선택적으로 치환된 방향핵 또는 할로겐 원자, 니트로그룹 또는 C1-C3알킬 또는 알콕시 그룹과 같은 치환제에 의해 선택적으로 치환된 벤질 라디칼을 나타낸다.
  2. 제1항에 있어서, 피롤리돈카르복사미드 라디칼이 DL 배열을 갖는 화합물.
  3. 제1항에 있어서, 피롤리돈카르복사미드 라디칼이 L 배열을 갖는 화합물.
  4. 제1항에 있어서, R이 3,4-디메톡시벤조일 라디칼을 나타내는 화합물.
  5. 제1항에 있어서, R이 H인 화합물.
  6. 제4항에 따른 유도체를 합성함에 있어서 중간체로 유용한 N-(3,4-디메톡시벤조일) 피로글루타민산.
  7. 제1항에 있어서, R이 4-메톡시벤조일 라디칼을 나타내는 화합물.
  8. 제7항의 유도체를 제조함에 있어서 중간체로 유용한 N-(4-메톡시벤조일) 피로글루타민산.
  9. 제1항에 있어서, R이 3,4-디메톡시페닐아세틸라디칼을 나타내는 화합물.
  10. 제9항에 따른 유도체를 제조함에 있어 중간체로 유용한 N-(3,4-디메톡시페닐아세틸) 피로글루타민산.
  11. 제1항에 있어서, R이 사이클로펜틸프로피오닐 라디칼을 나타내는 화합물.
  12. 제11항에 따른 유도체를 제조함에 있어서 중간체로 유용한 N-(사이클로펜틸피오닐) 피로글루타민산.
  13. 제1항에 있어서, R이 2-프로필펜탄오일 라디칼을 나타내는 화합물.
  14. 제13항에 따른 유도체를 제조함에 있어서 중간체로 유용한 N-(2-프로필펜탄오일) 피로글루타민산.
  15. 제1항에 있어서, R이 2-에틸헥산오일 라디칼을 나타내는 화합물.
  16. 제15항에 따른 유도체를 제조함에 있어서 중간체로 유용한 N-(2-에틸헥산오일) 피로글루타민산.
  17. 제1항에 있어서, R이 헥산오일 라디칼을 나타내는 화합물.
  18. 제17항에 따른 유도체를 제조함에 있어서 중간체로 유용한 N-헥산오일 피로글루타민산.
  19. 제1항에 따른 화합물을 최소한 하나 포함하거나 구성하고 있는 의약.
  20. 벤질 피로글루타메이트의 나트륨유도체를 알킬화 또는 아실화제와 반응시켜 벤질피로글루타메이트의 N-알킬 또는 N-아실 유도체를 생성하여 이것을 가수소분해한 후 불활성 용매에서 커플링제의 존재하에 아다만탄 아민과 반응시켜 일반식(Ⅰ)의 유도체를 제조하는 방법.
  21. 제20항에 있어서, N-알킬피로글루타민 또는 N-아실피로글루타민산을 반응성 유도체로 바꾸고 나서 불활성 용매에서 아다만탄 아민과 바람직하게는 수소 수용체와 반응시키는 방법.
  22. N-벤질옥시카르보닐피로글루타민산의 반응성 유도체를 제조하여 아다만탄아민과 반응시켜 생성물을 가수소분해 시킴으로써 제5항에 따른 화합물을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850008081A 1984-10-31 1985-10-31 아다만탄아민 유도체의 제조방법 KR920003837B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8416656 1984-10-31
FR84/16656 1984-10-31
FR8416656A FR2572399B1 (fr) 1984-10-31 1984-10-31 Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant

Publications (2)

Publication Number Publication Date
KR860003219A true KR860003219A (ko) 1986-05-21
KR920003837B1 KR920003837B1 (ko) 1992-05-15

Family

ID=9309181

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850008081A KR920003837B1 (ko) 1984-10-31 1985-10-31 아다만탄아민 유도체의 제조방법

Country Status (10)

Country Link
US (1) US4661512A (ko)
EP (1) EP0187052B1 (ko)
JP (1) JPS61109766A (ko)
KR (1) KR920003837B1 (ko)
AT (1) ATE49957T1 (ko)
AU (1) AU583543B2 (ko)
DE (1) DE3575715D1 (ko)
ES (1) ES8702888A1 (ko)
FR (1) FR2572399B1 (ko)
ZA (1) ZA858169B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3609152A1 (de) * 1986-03-19 1987-09-24 Bayer Ag Verfahren zur herstellung des (-)-antipoden des (e)-1-cyclohexyl-4,4-dimethyl- 3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-ens
FR2603888B1 (fr) * 1986-09-16 1990-12-21 Panmedica Sa Esters d'amino acides du trimethyl cyclohexanol, procede de preparation et utilisation comme medicaments
US5236946A (en) * 1986-09-16 1993-08-17 Panmedica S.A. Amino acid esters of cycloaliphatic alcohols and their use in treating lipemic disorders
US5652335A (en) * 1990-02-28 1997-07-29 Teikoku Seiyaku Kabushiki Kaisha Physiologically active substance well capable of permeating biomembrane
EP0668290B1 (en) * 1990-02-28 1998-11-11 Teikoku Seiyaku Kabushiki Kaisha Physiologically active substance well capable of permeating biomembrane
WO1995020951A1 (en) * 1994-02-01 1995-08-10 Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
US5880154A (en) * 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
JP2001518057A (ja) * 1995-07-07 2001-10-09 ダーハム ファーマシューティカルズ，エルエルシー 環状アミドおよびそれらの誘導体
DK0870757T3 (da) * 1997-04-10 2002-07-15 Pfizer Fluorsubstituerede adamantanderivater
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6808716B2 (en) * 1999-01-08 2004-10-26 Ruey J. Yu N-acetylamino acids, related N-acetyl compounds and their topical use
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
PT1513519E (pt) * 2002-06-03 2009-05-06 Novartis Ag Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
MXPA06012831A (es) * 2004-05-06 2007-01-26 Pfizer Nuevos compuestos de derivados de morfolina y prolina.
JP2007102047A (ja) * 2005-10-07 2007-04-19 Dainippon Printing Co Ltd 商品管理用タグ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) * 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
FR2622M (fr) * 1962-12-29 1964-06-29 Mundipharma Ag Nouveaux composés thérapeutiques.
US3345399A (en) * 1965-01-21 1967-10-03 Lilly Co Eli Carbamate esters of adamantane, mono-and di-methyladamantane and homoadamantane
US3374244A (en) * 1966-06-13 1968-03-19 Searle & Co N-(dialkylaminoalkyl)adamantanecarboxamides and related compounds
US3478055A (en) * 1966-06-15 1969-11-11 Tanabe Seiyaku Co Production of optically active n-acylprolines and prolines
US3682922A (en) * 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
BE754823A (fr) * 1969-08-13 1971-01-18 Merz & Co Derives de l'amonioadamantane et leur procede de preparation
JPS5581857A (en) * 1978-12-15 1980-06-20 Kyowa Hakko Kogyo Co Ltd Modifier of citrus fruit
US4273704A (en) * 1979-12-03 1981-06-16 G. D. Searle & Co. N-Adamantane-substituted tetrapeptide amides
US4296110A (en) * 1980-10-28 1981-10-20 E. I. Du Pont De Nemours And Company Antihypertensive I-substituted cyclic lactam-2-carboxylic acids
JPS5865269A (ja) * 1981-10-12 1983-04-18 Suntory Ltd ４置換（２ｓ，３ｓ，４ｓ）−２−カルボキシピロリジン−３−酢酸およびそのエステル
US4448972A (en) * 1982-02-22 1984-05-15 Smithkline Beckman Corporation Adamantyl containing intermediates
CS231221B1 (en) * 1982-06-29 1984-10-15 Martin Flegel L-alanyl-d-isoglutamine adamantylamide

Also Published As

Publication number Publication date
ZA858169B (en) 1986-06-25
ATE49957T1 (de) 1990-02-15
US4661512A (en) 1987-04-28
AU4884685A (en) 1986-05-08
EP0187052B1 (fr) 1990-01-31
JPS61109766A (ja) 1986-05-28
ES548357A0 (es) 1987-01-16
DE3575715D1 (de) 1990-03-08
ES8702888A1 (es) 1987-01-16
AU583543B2 (en) 1989-05-04
KR920003837B1 (ko) 1992-05-15
FR2572399B1 (fr) 1987-01-16
FR2572399A1 (fr) 1986-05-02
EP0187052A1 (fr) 1986-07-09

Similar Documents

Publication Publication Date Title
KR860003219A (ko) 아다만탄아민유도체의 제조방법
IE49647B1 (en) Non-ionic x-ray contrast agents
NO950849D0 (no) Derivater av valproin og 2-valproensyreamider og anvendelse som antikonvulsanter
BR9304481A (pt) Processo para preparar compostos, processo para preparar composiçóes farmacéuticas, compostos e composiçao farmaceutica
PT97993A (pt) Processo para a preparacao de derivados de amidas ciclicas e de composicoes farmaceuticas que os contem
ES8405757A1 (es) "un procedimiento para la preparacion de compuestos aromaticos hidroxilados".
EA200000484A1 (ru) Способ получения производных тиазолидиндиона
GB2285444A (en) Arylsulfonamide derivative and pharmaceutical composition containing the same
DE69214784D1 (de) Verfahren zur herstellung von cephalosporinzwischenverbindungen
KR870003107A (ko) 키산틴 유도체의 제조방법
KR850004460A (ko) 인돌의 제조방법
PT968189E (pt) Processo para a preparacao de acidos nicotinicos
KR980002053A (ko) 세펨 유도체와 이소옥사세펨 유도체의 제조방법
NO169076C (no) Anhydrider av 1-ethyl-6-fluor-7-klor-4-oxo-1,4-dihydro-kinolin-3-carboxylsyre og borsyrer
KR850005830A (ko) 2-알콕시아미노설포닐벤젠-설포닐우레아의 제조방법
BR9400817A (pt) Processo para preparar derivados de sulfoniluréia, processo para preparar derivados de sulfonilcloreto, composto hidróxido de 1-(((pirazolesulfonil)amino)carbonil) piridínio e processo para preparar compostos
PT88569A (pt) Substituierte 3-aminosydnonimine verfahren zu ihrer herstellungund ihre verwendung
FI93443B (fi) Menetelmä välituotteiden valmistamiseksi ja N-(2-hydroksietyyli)-2-hydroksimetyyli-3,4,5-trihydroksipiperidiinien syntetisoimiseksi
KR840004123A (ko) 포스포리피드 유도체의 제조방법
KR960700232A (ko) 신규시클로프로필유도체, 그 제조방법 및 용도(new cyclopropyl deri vatives, preparation method thereof and applications)
DK0434560T3 (da) Hidtil ukendte substituerede aminosyrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
DK0756593T3 (da) Fremgangsmåde til fremstilling af 2-piperazincarboxylsyrederivater
AU1012988A (en) New N-(1H-indol-4-yl)benzamide derivatives and also their salts, their application by way of medicinal products and the compositions containing them
GB1498996A (en) Omega-aminoalkanoic acid arylamides
KR890006656A (ko) 약물동력학적으로 개선된 세팔로스포린 유도체, 그의 제조방법 그를 함유하는 약제학적 조성물 및 합성 중간체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee